Summary & Overview
HCPCS A9546: Cobalt Co-57/58 Cyanocobalamin Diagnostic Dose
HCPCS Level II code A9546 represents a diagnostic radiopharmaceutical: cobalt Co-57/58 labeled cyanocobalamin (cyanocobalamin), billed per study dose up to 1 microcurie. Radiolabeled vitamin B12 tracers are used in nuclear medicine to evaluate specific physiological processes and to support imaging studies where vitamin B12 uptake or distribution is clinically relevant. Nationally, accurate coding of radiopharmaceuticals matters for clinical documentation, inventory control, and consistent payment processing across payers.
Key payers in the national context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of this radiopharmaceutical, typical sites of service where it is administered, and the payer landscape addressed in this publication. The report also covers coding benchmarks, common billing practices, and any notable policy updates that affect radiopharmaceutical billing and coverage for diagnostic studies.
This summary provides clinical context for coding teams, revenue cycle staff, and policy analysts seeking a concise reference on A9546, including what to expect in documentation requirements and where the service is typically performed. Data not available in the input will be identified in corresponding sections.
Billing Code Overview
HCPCS Level II code A9546 describes a diagnostic radiopharmaceutical: Cobalt Co-57/58, cyanocobalamin, per study dose, up to 1 microcurie. This product is used as a tracer in nuclear medicine diagnostic studies that require radiolabeled cyanocobalamin (vitamin B12) for imaging or functional assessment.
Service type: Diagnostic radiopharmaceutical / Nuclear medicine diagnostic study
Typical site of service: Hospital outpatient department, hospital-based nuclear medicine suite, or outpatient imaging center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to nuclear medicine for a vitamin B12 absorption or localization study using cobalt-labeled cyanocobalamin (A9546). The patient presents with unexplained macrocytic anemia, neurological symptoms suggestive of B12 deficiency, or prior gastric surgery affecting intrinsic factor. In the outpatient nuclear medicine department the technologist prepares and administers a diagnostic radiolabeled cyanocobalamin dose (Cobalt Co-57/58, up to 1 microcurie) per protocol. The workflow includes verification of indication and informed consent, radiopharmacy preparation and dose calibration, intravenous administration or enteral dosing per study design, timed imaging or gamma probe localization, and documentation of dose, lot, route, and patient monitoring. Typical sites of service are hospital-based outpatient nuclear medicine departments, freestanding imaging centers with radiopharmacy capability, or inpatient radiology/nuclear medicine suites when inpatient evaluation is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the study requires substantially greater resources or time than typical (rare for diagnostic tracer preparation but possible with complicated compounding or extended imaging protocols). |